INTERNATIONAL LIVER CANCER ASSOCIATION
ILCA Annual Conference 202417 - 19 October, 2024. Toronto
N. Poster
Poster title
Applicant name
Status
 |
|
|
|
| P-01 | Depth of response (DpR) and duration of response (DoR) are associated with overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC): Exploratory analyses of IMbrave150 | Masatoshi Kudo |  Received |
 |
|||
| P-02 | Growth patterns of early stage hepatocellular carcinoma according to LI-RADS categories | Sang Hyun Choi | Received |
|
|||
| P-3 | Using a combined index of methylated SEPT9 with existing tumor markers as a screening test for early-stage hepatocellular carcinoma | Issei Saeki | Received |
|
|||
| P-04 | Primary biliary cholangitis increases the risk of hepatocellular carcinoma and mortality | Jihye Lim | Received |
|
|||
| P-7 | Impact of SGLT2 Inhibitors on Hepatocellular Carcinoma Incidence in Patients with Type 2 Diabetes and Chronic Hepatitis B/C: A Korean Nationwide Cohort Study | Seong Hee Kang | Received |
|
|||
| P-08 | The Increasing Inefficiency of Liver Transplant Allocation and its Effect on Patients with Hepatocellular Carcinoma | Lauren Matevish | Received |
|
|||
| P-9 | Association Between Safety Net Hospitals and Treatment Delays in Hepatocellular Carcinoma | Zach Whitham | Received |
|
|||
| P-10 | Patient and physician expectations regarding disease and treatment in advanced hepatocellular carcinoma: the multicentric prospective PERCEPTION1 study | jean charles nault | Received |
|
|||
| P-12 | Unveiling the role of unfolded protein response in hepatocellular carcinoma behavior in TP53 and CTNNB1 genetic backgrounds | Josepmaria Argemi | Received |
|
|||
| P-14 | Modeling Hepatocellular Carcinoma by CRISPR Editing of Porcine Primary Hepatocytes | Lobna Elkhadragy | Received |
|
|||
| P-15 | Extensive molecular profiling in Predicting Survival in patients with cholangiocarcinoma treated with Cisplatin/gemcitabine plus durvalumab, a large real-life worldwide population | Andrea Casadei Gardini | Received |
|
|||
| P-16 | Combined anti-PD1 therapy relieves MDSC-mediated immunosuppression and reduces hepatocellular carcinoma regrowth after irreversible electroporation | Jihui Huo | Received |
|
|||
| P-18 | Molecular and cellular consequences of tumor-autonomous IL-6 signaling in cholangiocarcinoma | Virág Gehl | Received |
|
|||
| P-20 | Relationship between AURKA and PD-L1 Expression in HCC: The Regulatory Role of the Kinase in Immune Checkpoint Modulation | Luca Grisetti | Received |
|
|||
| P-21 | The role of lysine demethylase (KDM) families 3 and 5 in epi-therapy sensitive bile duct cancers | Yuewan Luo | Received |
|
|||
| P-23 | SUSD2 expressed by fibroblasts and immune cells shapes the tumour microenvironment in hepatocellular carcinoma | zaira rehman | Received |
|
|||
| P-24 | Characterization of the intratumoral immune microenvironment of hepatocellular carcinoma before ive internal radiation therapy (SIRT) and study of its prognostic value on response to treatment | Maria Stella Franzè | Received |
|
|||
| P-25 | Novel Integrated Index ASDAm-H1 for Diagnosing Early-stage Hepatocellular Carcinoma | Takahiro Yamasaki | Received |
|
|||
| P-26 | Survival Benefits of Combining Transarterial Chemoembolization with Radiotherapy versus Transarterial Chemoembolization Alone in Single Hepatocellular Carcinoma within BCLC Stage 0A | Jinhong Jung | Received |
|
|||
| P-31 | Recent advances in systemic therapy for advanced biliary tract cancer treatment: a systematic review and meta-analysis | Zhihao Li | Received |
|
|||
| P-32 | Primary and acquired mechanisms of resistance to ive Src Family Kinase inhibition in vitro and in patient-derived xenograft models of human cholangiocarcinoma | Hendrien Kuipers | Received |
|
|||
| P-33 | Demographics, Clinical Characteristics, Treatment Patterns, and Outcomes of Embolization-Eligible Patients with Hepatocellular Carcinoma (HCC): A Real-World Study of an Asian Pacific Cohort | Ravi Patel | Received |
|
|||
| P-34 | Resolving an old problem: High acceptance and uptake of HCV treatment in patients with liver cancer | Maria Fernanda Guerra | Received |
|
|||
| P-36 | Evolutionary dynamics of recurrent Hepatocellular Carcinoma (HCC) under divergent immune ion pressures. | Dr. Xun Zhao | Received |
|
|||
| P-37 | Development and validation of a prediction model for major adverse cardiac events in patients with hepatocellular carcinoma undergoing stereotactic body radiation therapy | Sang Min Yoon | Received |
|
|||
| P-38 | Impact of varices on bleeding risks and overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab | Jeayeon Park | Received |
|
|||
| P-39 | Impact of Hepatitis B Virus Infection on Efficacy and Safety of Pembrolizumab Gemcitabine and Cisplatin for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study | Quinn Humes | Received |
|
|||
| P-41 | Artificial intelligence MVI diagnosis model (MVL-DL) assisting prognostic stratification of hepatocellular carcinoma | Shiyi Liu | Received |
|
|||
| P-44 | Stereotactic Body Radiotherapy for Elderly Patients with Early Hepatocellular Carcinoma | Landon Chan | Received |
|
|||
| P-45 | Prognostic value of the timing of immune checkpoint inhibitors infusion in patients with advanced hepatocellular carcinoma | Alina Pascale | Received |
|
|||
| P-48 | Loss of SGK1 promotes resistance to T cell-mediated immunity for metastatic colonization | Zefan Zhang | Received |
|
|||
| P-53 | Role of ALBI score as a predictive factor for mortality in patients with hepatocellular carcinoma undergoing transarterial chemoembolization | Won Sohn | Received |
|
|||
| P-54 | The impact of performance scores on the Barcelona Clinic Liver Cancer staging system in HCC patients | Alexa Childs | Received |
|
|||
| P-55 | Development and validation of a deep learning model for detection of tertiary lymphoid structures on whole slide images in hepatocellular carcinoma | Shiyi Liu | Received |
|
|||
| P-56 | Early Recurrence of Hepatocellular Carcinoma Following Resection at a Western Center | Zach Whitham | Received |
|
|||
| P-57 | Impact of Oral Glucose Tolerance Test in Predicting Hepatocellular Carcinoma Development in Cirrhotic Patients: A Prospective Observational Study | Seong Hee Kang | Received |
|
|||
| P-58 | NOVEL APPROACHES FOR COMMUNITY RECRUITMENT FOR CHOLANGIOCARCINOMA GENETICS STUDY | Nellie Campbell | Received |
|
|||
| P-60 | A systematic review of prostate specific membrane antigen (PSMA) PET/CT in the diagnosis and staging of hepatocellular carcinoma (HCC) | Nicholas Hannah | Received |
|
|||
| P-62 | Safety and efficacy analysis of Cadonilimab in combination with Lenvatinib for unresectable hepatocellular carcinoma (uHCC) as first-line therapy: a retrospective study | Jinzhang Chen | Received |
|
|||
| P-63 | Second-line FOLFIRI vs FOLFOX after CisGem /- durvalumab in patients with advanced cholangiocarcinoma: a retrospective, single-center study | Valentina Zanuso | Received |
|
|||
| P-64 | Analysis of Varix bleeding complication after Atezolizumab plus Bevacizumab for advanced Hepatocellular carcinoma patients | Hee Yeon Kim | Received |
|
|||
| P-66 | Sequential treatment of immunotherapy and liver transplantation for hepatocellular carcinoma | Pin-Jung Chen | Received |
|
|||
| P-67 | Atezolizumab plus bevacizumab for patients with unresectable hepatocellular carcinoma and high hepatitis B viral load: updated safety and efficacy analysis | Chiun Hsu | Received |
|
|||
| P-68 | Propensity ScoreWeighted Analysis of Neoadjuvant Therapy Versus Upfront Surgical Resection in Patients with Biliary Tract Cancers | Elsa Hallab | Received |
|
|||
| P-69 | Observational study of patients with unresectable hepatocellular carcinoma treated with regorafenib in routine clinical practice (REFINE): Subgroup analysis by prior transarterial chemoembolization (TACE) and transarterial radioembolization (TARE) | Rego OpenHealth | Received |
|
|||
| P-71 | LIVER-R a global real-world (RW) evidence platform for patients (pts) treated with durvalumab (D)-based regimens in hepatobiliary cancers (HBC) | Helen Sherratt | Received |
|
|||
| P-72 | A prospective, observational study of the effectiveness of systemic therapies in patients with unresectable hepatocellular carcinoma following first-line immuno-oncology combination therapy (REFINE-IO) | Rego OpenHealth | Received |
|
|||
| P-73 | Metabolic plasticity in hepatocellular carcinoma induces a shift from glutaminolysis to glutaminogenesis under hypoxia | Vincent Tambay | Received |
|
|||
| P-75 | Profile of immune-related adverse events and treatment outcomes in first-line immunotherapy for hepatocellular carcinoma | Marta Fortuny | Received |
|
|||
| P-76 | Trends in initial anti-cancer therapy for HCC patients over 9 years | Alexa Childs | Received |
|
|||
| P-77 | Evaluation of In Vitro Proliferation of Novel Hepatocellular Carcinoma Cell Models Developed by CRISPR Editing of Primary Porcine Hepatocytes | Caitlyn Castillo | Received |
|
|||
| P-79 | Impact of add-on gadoxetic acid-enhanced abbreviated magnetic resonance imaging on ultrasound hepatoma surveillance for liver cirrhosis- a randomized study | Jing-Houng Wang | Received |
|
|||
| P-80 | Limited Performance of the Steatosis-Associated Fibrosis Estimator score in Young Asian Subjects with Steatotic Liver Disease | Jiwon Yang | Received |
|
|||
| P-81 | Salvage Hepatectomy for Recurrent Hepatocellular Carcinoma after Radiofrequency Ablation | Jai Young Cho | Received |
|
|||
| P-83 | Hepatocellular carcinoma following direct-acting antiviral therapy in Korean patients with HBV/HCV co-infection | Young Joo Park | Received |
|
|||
| P-84 | Phase Ib trial of durvalumab plus tremelimumab in combination with particle therapy in advanced hepatocellular carcinoma patients with macrovascular invasion: DEPARTURE trial | Sadahisa Ogasawara | Received |
|
|||
| P-89 | The Differential Regulatory Role of Aurora Kinase A in Chronic Liver Disease and Hepatocellular Carcinoma | Luca Grisetti | Received |
|
|||
| P-91 | Adverse effects associated with the use of bevacizumab in patients with hepatocellular carcinoma. A real-life study. | Marta Garcia-Calonge | Received |
|
|||
| P-92 | Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus transhepatic arterial infusion chemotherapy (HAIC) with FOLFOX regimen for resectable multinodular CNLC Ib/IIa hepatocellular carcinoma (CAR_Hero study) | Tao Peng | Received |
|
|||
| P-94 | Nintedanib alleviates metabolic-associated fatty liver disease in mice by elimination of activated fibroblasts. | deok hwa seo | Received |
|
|||
| P-95 | Endothelial compartment expression of prostate-specific membrane antigen immunohistochemistry accurately discriminates hepatocellular carcinoma from benign tissue | Nicholas Hannah | Received |
|
|||
| P-98 | The growth and differentiation factor 11 increases the effectiveness of HCC chemotherapy | Natanael German-Ramirez | Received |
|
|||
| P-99 | A prognostic score for survival in patients with hepatocellular carcinoma under systemic treatment. | Leonardo da Fonseca | Received |
|
|||
| P-100 | Real World Evidence of Effectiveness of Lenvatinib in Patients with Hepatocellular Carcinoma (HCC) in Two Tertiary Hospitals in the Philippines | Charles Jeffrey Tan | Received |
|
|||
| P-102 | Hepatocellular carcinoma care during the COVID-19 pandemic: a single-centre experience missing patients and robust screening | Nicholas Hannah | Received |
|
|||
| P-103 | Beneficial effect of combined radiation therapy in atezolizumab plus bevacizumab treatment of hepatocellular carcinoma patients with main portal vein tumor thrombosis | Kiyoun Yi | Received |
|
|||
| P-105 | Critical Care Needs for Hepatocellular Carcinoma Patients Receiving Checkpoint Inhibitors | Marta Fortuny | Received |
|
|||
| P-106 | Using EVendo Score (ES) to Predict Varices Needing Treatment (VNT) in Hepatocellular Carcinoma (HCC) Patients for Atezolizumab-Bevacizumab (AB) | Suat Ying Lee | Received |
|
|||
| P-110 | The plasticity of cancer stemness in hepatocellular carcinoma: The therapeutics of exosome through tumor microenvironment. | Ming-Chin Yu | Received |
|
|||
| P-111 | Selective internal radiation therapy (SIRT) for hepatocellular carcinoma (HCC): Kings College Experience | ilkay Ergen | Received |
|
|||
| P-112 | Status of Safety and Management of Immunotherapy in Patients with Primary Liver Cancer:A Multicenter Survey | Li Xu | Received |
|
|||
| P-113 | Hepatocellular Carcinoma Imaging using PSMA PET/CT A prospective pilot trial (Hepa-SMART) | Nicholas Hannah | Received |
|
|||
| P-114 | Machine learning model reveals roles of interferon-stimulated genes in sorafenib-resistant hepatocellular carcinoma | DeokHwa Seo | Received |
|
|||
| P-115 | Ehrlichia: oncogenic infectious agent responsible for hepatic physiological deregulation. | Maria Jose Tintel | Received |
|
|||
| P-116 | Identification and management of synchronous liver tumours of differing subtype: an ongoing challenge | Syed Alam | Received |
|
|||
| P-117 | COMBINATION OF RADIATION THERAPY IMPROVE EFFICACY OF ATEZOLIZUMAB PLUS BEVACIZUMAB (ATEBEVA) THERAPY IN ADVANCED HEPATOCELLULAR CARCINOMA WITH HIGH RISK FACTOR (HUGE TUMOR, BILIARY AND MAIN PORTAL VEIN INVASION) | SANGYOUN HWANG | Received |
|
|||
| P-118 | Whole-liver ive internal radiation therapy in a liver transplant patient with recurrent hepatocellular carcinoma: A Case Report | Emilie Lauridsen | Received |
|
|||
| P-119 | MANAGEMENT OF EARLY STAGE HEPATOCARCINOMA IN A TERTIARY CARE HOSPITAL WITHOUT LIVER TRANSPLANTATION | Raisa Quiñones Castro | Received |
|
|||
| P-121 | Clinical outcomes of patients (pts) with unresectable and advanced hepatocellular carcinoma (HCC) treated with first-line (1L) atezolizumab plus bevacizumab (atezo-bev) or durvalumab plus tremelimumab (STRIDE): a retrospective, single-center study | angelo pirozzi | Received |
|
|||
| P-123 | Validation and comparative assessment of a machine learning model for predicting hepatocellular carcinoma risk in patients with chronic hepatitis B infection | Yashasavi Sachar | Received |
|
|||
| P-124 | Influence of T- Consciousness Fields on Diethylnitrosamie-Induced Hepatocellular carcinoma in Mice | Mahyar Ramazanzade | Received |
|
|||
| P-125 | The clinical efficacy and safety of Sintilimab plus Anlotinib for unresectable intrahepatic cholangiocarcinoma: A prospective, single-arm phase II study | Xin-Rong Yang | Received |
|
|||
| P-126 | The efficacy and safety of Toripalimab combined with Sorafenib for unresectable hepatocellular carcinoma: An open-label, prospective, single-arm phase II study | Wen-Jing Zheng | Received |
|
|||
| P-128 | A multimodal atlas of hepatocellular carcinoma reveals convergent evolutionary paths and bad apple effect on clinical trajectory | YING ZHANG | Received |
|
|||
| P-130 | Phase I/II study of the CXCR2 inhibitor, AZD5069, in combination with Durvalumab, in patients (pts) with advanced Hepatocellular Carcinoma (HCC) | Thomas Ronald Jeffry Evans | Received |
|
|||
ILCA Annual Conference 2024
17 - 19 October, 2024. Toronto
Search and consult posters online
in an exclusive section
for each poster
in an exclusive section
for each poster
ACTIVE FROM 08/10/2024 TO 17/10/2025
Poster
Gallery
Gallery
Upload
Poster
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
Forum
|
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.
|
|
||
|
||||
Poster submission deadline 30/09/2024
|
|
